The first antibody-drug conjugate directed at an internalizing tumor-associated antigen produced no objective responses across twenty-six patients and was stopped by ocular toxicity.1

Among nearly three thousand patients given ADCs for lung cancer, 30.9% experienced a pulmonary adverse event.2

A target that has failed three times has either been disproved or never properly engineered. The evidence points at the second.

Please note: Voxeda Bio operates in a stealth capacity.

Your message reaches the team directly. We keep your details for correspondence and no other purpose. Privacy.